Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application entities : Biogen inc. save search
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-03-05 (Crawled : 00:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.09%
H: 0.79%
C: -0.09%
treatment fda disease application grants license approval alzheimer’s review
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Published: 2023-02-27 (Crawled : 00:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.53%
H: 1.02%
C: 0.78%
lecanemab medical application license review china
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:20) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:00) - globenewswire.com
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.27%
H: 6.75%
C: 3.25%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.51%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression major depressive disorder
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Published: 2023-01-26 (Crawled : 00:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.15%
H: 1.21%
C: -0.78%
treatment lecanemab disease application alzheimer’s authorization
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN
Published: 2023-01-16 (Crawled : 01:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
| Email alert
Add to watchlist
lecanemab disease alzheimer's japan antibody application authorization anti-amyloid beta
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Published: 2023-01-10 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.14%
H: 1.23%
C: 1.13%
treatment europe lecanemab disease alzheimer's application authorization
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-01-07 (Crawled : 08:20) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease alzheimer's application license approval
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
Published: 2022-12-09 (Crawled : 13:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.34%
C: -1.29%
biib800 actemra fda candidate biosimilar application license
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2022-12-06 (Crawled : 13:20) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.25%
H: 0.44%
C: -4.15%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.18%
H: 0.97%
C: -0.26%
treatment drug application therapeutics depression submission major depressive disorder
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Published: 2022-10-17 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.97%
H: 1.62%
C: -0.62%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.54%
H: 2.99%
C: 1.32%
drug extension application review
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published: 2022-07-26 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 3.54%
C: 2.01%
fda drug genetic als application grants review
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-07-05 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.98%
H: 1.73%
C: 1.35%
fda disease alzheimer's application grants license approval review lecanemab
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-05-09 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
fda disease alzheimer's application license approval submission alzheimer’s lecanemab
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
Published: 2022-05-02 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -1.12%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.95%
H: 1.37%
C: 0.49%
treatment drug application therapeutics food potential submission major depressive disorder
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
Published: 2022-03-03 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -2.32%
H: 0.0%
C: 0.0%
ema application approval system antibody submission lecanemab anti-amyloid beta
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
Published: 2021-10-19 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.11%
H: 1.59%
C: -8.47%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.1%
H: 0.61%
C: -0.69%
new drug food application drug submission
Biosimilars Market by Application and Geography | Global Forecast to 2025 | 17,000+ Technavio Research Reports
Published: 2021-09-22 (Crawled : 00:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.38%
H: 1.5%
C: 0.3%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.92%
H: 0.5%
C: 0.01%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 1.51%
H: 2.09%
C: -0.17%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.53%
H: 1.43%
C: 1.2%
research application biosimilar
Global Biotechnology Market (2020 to 2026) - by Application, End-user and Region
Published: 2021-08-25 (Crawled : 12:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.41%
H: 0.47%
C: 0.43%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.17%
H: 0.12%
C: -0.83%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.42%
H: 0.01%
C: -0.75%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.19%
H: 0.79%
C: 0.47%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.62%
H: 0.13%
C: -1.29%
biotech technology iot application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.